Hong Zhang

Summary

Affiliation: Biogen Idec
Country: USA

Publications

  1. ncbi BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
    Hong Zhang
    Biogen Idec, 5200 Research Place, San Diego, CA, USA
    Int J Cancer 126:1226-34. 2010
  2. ncbi Discovery of 4-aryl-2-oxo-2H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay
    William Kemnitzer
    EpiCept Corporation, Inc 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 18:5571-5. 2008
  3. ncbi Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity
    Hong Zhang
    Conforma Therapeutics Corporation, San Diego, CA, USA
    Int J Cancer 120:918-26. 2007
  4. ncbi BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
    Karen Lundgren
    Biogen Idec, 5200 Research Place, San Diego, CA 92122, USA
    Mol Cancer Ther 8:921-9. 2009
  5. ncbi Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring
    Nilantha Sirisoma
    EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 20:2330-4. 2010
  6. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions
    William Kemnitzer
    EpiCept Corporation, San Diego, CA 92121, USA
    J Med Chem 51:417-23. 2008
  7. ncbi Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration
    Nilantha Sirisoma
    EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, California 92121, USA
    J Med Chem 52:2341-51. 2009
  8. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions
    William Kemnitzer
    Maxim Pharmaceuticals, Inc, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 15:4745-51. 2005
  9. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group
    William Kemnitzer
    Maxim Pharmaceuticals, Inc, 6650 Nancy Ridge Drive, San Diego, California 92121, USA
    J Med Chem 47:6299-310. 2004
  10. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions
    William Kemnitzer
    EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, California 92121, USA
    J Med Chem 50:2858-64. 2007

Collaborators

  • Shailaja Kasibhatla
  • Francis Burrows
  • Henriette Gourdeau
  • Lin Zhang
  • Adeela Kamal
  • Yan Wang
  • Karen Lundgren
  • Quan Yang
  • Martin Michaelis
  • Xiaoying Yin
  • William Kemnitzer
  • Songchun Jiang
  • John Drewe
  • Ben Tseng
  • Sui Xiong Cai
  • Nilantha Sirisoma
  • Serge Lamothe
  • Candace Crogan-Grundy
  • Real Denis
  • Giorgio Attardo
  • Christopher M Pleiman
  • Azra Pervin
  • Mark B Anderson
  • J Adam Willardsen
  • Jianghong Zhao
  • Naveen Dakappagari
  • Gary Mather
  • Charles Blais
  • Lifen Xu
  • Denis Labreque
  • Shaojuan Jia
  • Shabnam Tangri
  • Annalee Estrellado
  • Laura Neely
  • Lori Hipolito
  • Khanh Hoang
  • Vijay Baichwal
  • Gary G Mather
  • Kevin Jessing
  • Monica Bubenick
  • Raouf Hussain
  • Candace Crogan Grundy
  • Sylvie Charron
  • Jennifer Dodd
  • Nancy Barriault
  • Denis Labrecque
  • Louis Vaillancourt
  • Karen Meerovitch
  • John Herich
  • Rabindra Rej
  • Richard Storer
  • David Bouffard

Detail Information

Publications18

  1. ncbi BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
    Hong Zhang
    Biogen Idec, 5200 Research Place, San Diego, CA, USA
    Int J Cancer 126:1226-34. 2010
    ....
  2. ncbi Discovery of 4-aryl-2-oxo-2H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay
    William Kemnitzer
    EpiCept Corporation, Inc 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 18:5571-5. 2008
    ..These 4-aryl-2-oxo-2H-chromenes are a series of potent apoptosis inducers with potential advantage over the 4-aryl-2-amino-4H-chromenes series via elimination of the chiral center at the 4-position...
  3. ncbi Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity
    Hong Zhang
    Conforma Therapeutics Corporation, San Diego, CA, USA
    Int J Cancer 120:918-26. 2007
    ..These results indicate that monomeric and dimeric Hsp90 inhibitors have distinct biological profiles and work differentially toward target inhibition...
  4. ncbi BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
    Karen Lundgren
    Biogen Idec, 5200 Research Place, San Diego, CA 92122, USA
    Mol Cancer Ther 8:921-9. 2009
    ..Together, these data show that BIIB021 is a promising new oral inhibitor of Hsp90 with antitumor activity in preclinical models...
  5. ncbi Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring
    Nilantha Sirisoma
    EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 20:2330-4. 2010
    ..Through the SAR study, several 5- or 6-substituted analogs, such as 2a and 2c, were found to have potencies approaching that of lead compound N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine (1g, EP128495, MPC-6827, Azixa)...
  6. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions
    William Kemnitzer
    EpiCept Corporation, San Diego, CA 92121, USA
    J Med Chem 51:417-23. 2008
    ..Compound 2d was identified as a highly potent apoptosis inducer with an EC50 value of 2 nM and a highly potent inhibitor of cell growth with a GI50 value of 0.3 nM in T47D cells...
  7. ncbi Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration
    Nilantha Sirisoma
    EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, California 92121, USA
    J Med Chem 52:2341-51. 2009
    ..It also has excellent blood brain barrier penetration, and is highly efficacious in human MX-1 breast and other mouse xenograft cancer models...
  8. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions
    William Kemnitzer
    Maxim Pharmaceuticals, Inc, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 15:4745-51. 2005
    ....
  9. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group
    William Kemnitzer
    Maxim Pharmaceuticals, Inc, 6650 Nancy Ridge Drive, San Diego, California 92121, USA
    J Med Chem 47:6299-310. 2004
    ....
  10. ncbi Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions
    William Kemnitzer
    EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, California 92121, USA
    J Med Chem 50:2858-64. 2007
    ..Compound 2h was identified to be a highly potent apoptosis inducer with an EC50 of 5 nM and a highly potent inhibitor of cell proliferation with a GI50 of 8 nM in T47D cells...
  11. ncbi Identification of new biomarkers for clinical trials of Hsp90 inhibitors
    Hong Zhang
    Conforma Therapeutics Corp, 9393 Towne Center Drive, Suite 240, San Diego, CA 92121, USA
    Mol Cancer Ther 5:1256-64. 2006
    ....
  12. ncbi An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors
    Naveen Dakappagari
    Department of Clinical Sciences, Biogen Idec, San Diego, CA 92122, USA
    Biomarkers 15:31-8. 2010
    ....
  13. ncbi Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity
    Nilantha Sirisoma
    EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, California 92121, USA
    J Med Chem 51:4771-9. 2008
    ....
  14. ncbi Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo
    Xiaoying Yin
    Department of Otolaryngology/Head and Neck Surgery and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina and Conforma Therapeutics, San Diego, California, USA
    Clin Cancer Res 11:3889-96. 2005
    ..These results suggest that this novel ansamycin-based Hsp90 inhibitor affects multiple pathways involved in tumor development and progression and may represent a new strategy for the treatment of HNSCC patients...
  15. ncbi Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors
    Han-Zhong Zhang
    Maxim Pharmaceuticals, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    J Med Chem 49:1198-201. 2006
    ..Z-Leu-Gln(NMe(2))-fmk (6a) was found to be a potent inhibitor with low toxicity in cells, protecting cells with an EC(50) value of 2.5 microM and exhibiting a selectivity index of >40...
  16. ncbi Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity
    Shailaja Kasibhatla
    Maxim Pharmaceuticals, Inc, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA
    Mol Cancer Ther 3:1365-74. 2004
    ....
  17. ncbi Hsp90 activation and cell cycle regulation
    Francis Burrows
    Department of Biology, Conforma Therapeutics Corporation, San Diego, California 92121, USA
    Cell Cycle 3:1530-6. 2004
    ..In this article, the implications of this discovery are discussed, with particular reference to cell cycle regulation in normal and malignant cells, and the consequences of inducing cell cycle arrest with Hsp90 inhibitors...
  18. ncbi Targeting multiple signal transduction pathways through inhibition of Hsp90
    Hong Zhang
    Department of Biology, Conforma Therapeutics Corporation, 9393 Towne Centre Dr, 92121, San Diego, CA 92121, USA
    J Mol Med 82:488-99. 2004
    ..Thus these small molecule inhibitors have proved not only to be of great value in identifying new Hsp90 client proteins and in understanding the biology of Hsp90 but are also promising therapeutics in a variety of tumors...